Moreover, there are emerging novel bispecific antibodies targeting both PD-(L)1 and VEGF, such as ivonescimab (AK112), which is combined with CP/EP in a phase Ib ongoing clinical trial in first-line ES-SCLC (NCT05116007). This evidence concerns the gene CP and small cell lung carcinoma.